Protection of the ischemic myocardium: dose-response relationships with glucocorticoids in filtered cardioplegic solutions.
A concentration-responsive study of supplementation with methyl prednisolone sodium succinate (MPSS: 0-10-100-500-1000 mg/l) to a potassium-based crystalloid cardioplegic solution, administered under hypothermic conditions, has been undertaken in the isolated working rat heart. The solution was filtered through a very fine filter (0.22 micron), thereby excluding particles able to increase vascular resistance and reduce postischemic performance. The solution was administered intermittently at a constant flow rate during 180 min of ischemia at 20 degrees C. The per cent postischemic recovery of aortic flow rate for the following concentrations of MPSS was: 0 mg/l 57%; 10 mg/l 49%; 100 mg/l 52%; 500 mg/l 38%; and 1000 mg/l 28%. MPSS supplementation did not improve upon any of the physiological, enzymatic or metabolic (total tissue high-energy phosphates, lactate, glycogen, Ca++) variables. The highest concentrations (500 and 1000 mg/l) of MPSS decreased postischemic performance. The hearts perfused with sodium succinate in a concentration equimolar to MPSS 1000 mg/l recovered less than the hearts subjected to unmodified cardioplegia. It is concluded that MPSS does not confer any additional protection to a potassium-based, calcium-containing crystalloid cardioplegic solution when it is effectively filtered. High concentrations of MPSS may prove toxic to the ischemic myocardium.